Dentsply Sirona (XRAY) Tops Q4 EPS by 23c, Revenues Beat; Offers FY21 EPS/Revenues Guidance Above Consensus

Dentsply Sirona (NASDAQ: XRAY) reported Q4 EPS of $0.87, $0.23 better than the analyst estimate of $0.64. Revenue for the quarter came in at $1.08 billion versus the consensus estimate of $995.7 million.

Don Casey, Chief Executive Officer, commented “Our fourth quarter results reflect the continued focus on disciplined execution and the gradual recovery in global dental markets. Our team delivered strong operational performance, exceeding our expectations across most metrics including operating margin expansion, healthy EPS growth and cash flow generation. We capped off the year with the strategic acquisition of Byte, a rapidly growing direct-to-consumer, doctor-directed clear aligner company. This acquisition is key to accelerating our growth in the clear aligner space. While uncertainty remains on the timing and extent of a full recovery in the dental market, our 2021 outlook reflects our confidence in our portfolio and our commitment to driving growth through strategic investments.”

GUIDANCE:

Dentsply Sirona sees FY2021 EPS of $2.60-$2.80, versus the consensus of $2.39. Dentsply Sirona sees FY2021 revenue of $4-4.3 billion, versus the consensus of $3.86 billion.

We expect fiscal year 2021 revenue in the range of $4.0B to $4.3B, up 20% to 30% on a reported basis and up 15% to 25% on an organic basis1. We expect adjusted operating income margin2 of at least 20%. FY2021 non-GAAP EPS is expected to be in the range of $2.60 to $2.80.

For earnings history and earnings-related data on Dentsply Sirona (XRAY) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Merck (MRK) hikes outlook for 2024 as Q1 print beats analyst estimates
• Applied Industrial Technologies (AIT) Tops Q3 EPS by 8c; Updates outlook